Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 5/20 | 0.64 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | LIG1 | P18858 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | ALPL | P05186 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8049985 | 0.94 | ESR2 (0.58) | ESR2MAP1LC3BHRH3TDP1PDE4A | |
| SCHEMBL14403055 | 0.89 | ESR2 (0.78) | ESR2HRH3TDP1PDE4APDE4B | |
| SCHEMBL717834 | 0.88 | ESR2 (0.50) | ESR2MAP1LC3BTDP1PDE4APDE4B | |
| SCHEMBL10348022 | 0.82 | ESR2 (0.69) | ESR2HRH3TDP1PDE4APDE4B | |
| SCHEMBL18161913 | 0.81 | KDM1A (0.48) | ESR2MAP1LC3BTDP1KDM1APOLB | |
| SCHEMBL1066184 | 0.81 | KDM1A (0.48) | ESR2MAP1LC3BTDP1KDM1APOLB | |
| Hydrogen Sulfide SCHEMBL28219443 | 0.79 | KDM1A (0.46) | ESR2MAP1LC3BKDM1APOLB | |
| Ammonia Solution, Strong SCHEMBL22408764 | 0.79 | KDM1A (0.46) | ESR2MAP1LC3BKDM1APOLB | |
| SCHEMBL20010457 | 0.78 | ESR2 (0.39) | ESR2MAP1LC3BKDM1A | |
| SCHEMBL7199316 | 0.78 | ESR2 (0.48) | ESR2HRH3PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673431-A1 | HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | Novartis AG (CH) | 2026-01-07 | — | — | EP | disclosed |
| US-12129246-B1 | Hydroquinazoline derivatives for the treatment of a disease or disorder | NOVARTIS AG (CH) | 2024-10-29 | — | — | US | disclosed |
| US-20240336598-A1 | HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2024-10-10 | — | — | US | disclosed |
| WO-2024180499-A1 | HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS AG (CH) | 2024-09-06 | — | — | WO | disclosed |
| WO-2024149378-A1 | QUINOLINONE COMPOUND AND NAPHTHYRIDINONE COMPOUND AND USE THEREOF | 上海超阳药业有限公司 | 2024-07-18 | — | — | WO | disclosed |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
| CN-109952300-B | 5-or 8-substituted imidazo [1,5-a ] pyridines | 百济神州有限公司 | 2022-01-18 | — | — | CN | disclosed |
| US-11179710-B2 | Direct palladium-catalyzed aromatic fluorination | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-11-23 | — | — | US | disclosed |
| US-11179710-B2 | Direct palladium-catalyzed aromatic fluorination | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3426654-B1 | DIRECT PALLADIUM-CATALYZED AROMATIC FLUORINATION | HARVARD COLLEGE (US) | 2021-10-20 | — | — | EP | disclosed |
| EP-0009386-B1 | 2,10-DISUBSTITUTED DIBENZO(B,D)PYRANS AND BENZO(C)QUINOLINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. (US) | 1982-11-17 | — | — | EP | disclosed |
| US-4340737-A | CNS AGENTS, HYPOTENSIVES, DIURETICS AND AGENTS FOR TREATMENT OF GLAUCOMA | PFIZER INC. (US) | 1982-07-20 | — | — | US | disclosed |
| US-4329353-A | ANTIEMETIC AND NEUROLEPTIC AGENTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 1982-05-11 | — | — | US | disclosed |
| EP-0035902-A1 | 1-(4-Aryl-cyclohexyl)piperidine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1981-09-16 | — | — | EP | disclosed |
| EP-0034415-A1 | 1-(Cyclohexyl or cyclohexenyl)-4-aryl-4-piperidinecarboxylic acid derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1981-08-26 | — | — | EP | disclosed |
| US-4260764-A | ANALGESICS, TRANQUILIZERS | PFIZER INC. (US) | 1981-04-07 | — | — | US | disclosed |
| US-4243674-A | HYPOTENSIVE AGENTS; ANALGESICS; ANTISECRETORY AGENTS; ANTIBODY INHIBITORS, AND TRANQUILIZERS | PFIZER INC. (US) | 1981-01-06 | — | — | US | disclosed |
| US-4206225-A | ANALGESICS | PFIZER INC. (US) | 1980-06-03 | — | — | US | disclosed |
| EP-0009386-A1 | 2,10-Disubstituted dibenzo(b,d)pyrans and benzo(c)quinolines and pharmaceutical compositions thereof | PFIZER INC. (US) | 1980-04-02 | — | — | EP | disclosed |
| US-4143139-A | ANALGESICS, HYPOTENSIVES, IMMUNOSUPPRESSANTS, TRANQUILIZERS, ANTISECRETORY, ANTI-ANXIETY | PFIZER INC. (US) | 1979-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12129246-B1 | Hydroquinazoline derivatives for the treatment of a disease or disorder | RECQL, NRAS, RAB1A | ESR2 3779/4885MAP1LC3B 2447/4885HRH3 17/4885 |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | ESR2 4547/4885MAP1LC3B 2880/4885HRH3 3323/4885 |
| US-11179710-B2 | Direct palladium-catalyzed aromatic fluorination | KRAS, NRAS, DDT | ESR2 2276/4885MAP1LC3B 3919/4885HRH3 155/4885 |
| US-20240336598-A1 | HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | RECQL, NRAS, RAB1A | ESR2 3779/4885MAP1LC3B 2447/4885HRH3 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.